Search Results - anti-cancer

3 Results

Sort By:

PIM-Targeted PROTACs

Abstract: Proviral Integration for the Moloney murine leukemia virus (PIM) kinases are overexpressed in many solid cancers – including prostate, breast, colon, endometrial, gastric and pancreatic. High of PIM1 expression is predictive of poor survival in multiple cancer types. While several selective pan-PIM inhibitors were developed and tested in clinical...

Published: 4/8/2024 | Inventor(s): John Brognard, Rolf Swenson, Pedro Torres-Ayuso, Venkatareddy Sabbasani, Dawid Mehlich, Noel Warfel

Keywords(s): anti-cancer, Brognard, Chemotherapy Resistance, Kinase, PIM, PIM kinase-targeting proteolysis-targeting chimeras, PROTACs, solid tumors, Swenson, THERAPY

Category(s): Collaboration Sought > Collaboration, Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology

Identification and Use of Heterocyclic Alcohol Compounds for the Treatment of SULT1A1-expressing Cancers

This technology includes the identification and use of heterocyclic alcohol compounds, including RITA and N-BIC, for the treatment of SULT1A1-expression cancers. A high-throughput screen (qHTS) was performed using >1,000 caner cell lines identified a compound called YC-1 (also called Lificiguat) that is effective across cancer cell types that express...

Published: 7/25/2024 | Inventor(s): Min Shen, Ke Kong, Toble Lee, Samarjit Patnaik, Olivia Lee, Jonathan Shrimp, Mindy Davis, Juan Marugan, Wei Zhao, Matthew Hall

Keywords(s): Agents, Alcohol, anti-cancer, Class, compounds, HETEROCYCLIC, SULT1A1-dependent, VCXXXX, WKXXXX, XCXXXX, XEXXXX

Category(s): Application > Research Materials, Application > Therapeutics, Application > Diagnostics, TherapeuticArea > Oncology

Novel Therapeutic Compounds for Treatment of Cancer and Immune Disorders

The global market for cancer therapeutics is over $40 billion and is anticipated to continue to rise in the future. There remains a significant unmet need for therapeutics for cancers that affect blood, bone marrow, and lymph nodes and the immune system, such as leukemia, multiple myeloma, and lymphoma. The proteasome inhibitor bortezomib, which may...

Published: 7/25/2024 | Inventor(s): Yihong Ye, William Trenkle, Adrian Wiestner

Keywords(s): anti-cancer, Bortezomib, CANCER, CB5AXX, CB5EXX, CB5XXX, CB6XXX, CBXXXX, CXXXXX, DB4AXX, DB4XXX, DBXXXX, Diacyl, DXXXXX, ERAD, Hematologic, HYDRAZINE, Hydrazone, immunosuppressant, inhibitor, Patent Category - Chemistry, Proteasome, Proteasome inhibitor, retroviral, tumor

Category(s): Collaboration Sought > Licensing, Application > Therapeutics, TherapeuticArea > Oncology, TherapeuticArea > Infectious Disease, TherapeuticArea > Immunology